Pyun Jung-Min, Youn Young Chul, Park Young Ho, Kim SangYun
Department of Neurology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea.
Department of Neurology, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
Front Neurol. 2023 Jan 17;13:1028448. doi: 10.3389/fneur.2022.1028448. eCollection 2022.
There has been significant development in blood-based biomarkers targeting amyloidopathy of Alzheimer's disease (AD). However, the guidelines for integrating such biomarkers into AD diagnosis are still inadequate. Multimer Detection System-Oligomeric Amyloid-β (MDS-OAβ) as a plasma biomarker detecting oligomerization tendency is available in the clinical practice.
We suggest how to interpret the results of plasma biomarker for amyloidopathy using MDS-OAβ with neuropsychological test, brain magnetic resonance imaging (MRI), and amyloid PET for AD diagnosis. Combination of each test result differentiates various stages of AD, other neurodegenerative diseases, or cognitive impairment due to the causes other than neurodegeneration.
A systematic interpretation strategy could support accurate diagnosis and staging of AD. Moreover, comprehensive use of biomarkers that target amyloidopathy such as amyloid PET on brain amyloid plaque and MDS-OAβ on amyloid-β oligomerization tendency can complement to gain advanced insights on amyloid-β dynamics in AD.
针对阿尔茨海默病（AD）淀粉样病变的血液生物标志物已有显著进展。然而，将此类生物标志物纳入AD诊断的指南仍不完善。多聚体检测系统-寡聚淀粉样β蛋白（MDS-OAβ）作为一种检测寡聚化倾向的血浆生物标志物已应用于临床实践。
我们建议如何结合神经心理学测试、脑磁共振成像（MRI）以及用于AD诊断的淀粉样蛋白PET，利用MDS-OAβ来解读淀粉样病变血浆生物标志物的检测结果。各项检测结果的组合可区分AD的不同阶段、其他神经退行性疾病或由神经退行性变以外原因导致的认知障碍。
系统的解读策略有助于AD的准确诊断和分期。此外，综合使用针对淀粉样病变的生物标志物，如检测脑淀粉样斑块的淀粉样蛋白PET和检测淀粉样β蛋白寡聚化倾向的MDS-OAβ，可相互补充，以深入了解AD中淀粉样β蛋白的动态变化。
